Below are the most recent publications written about "Inhibitory Concentration 50" by people in Profiles.
-
Srour AM, Panda SS, Mostafa A, Fayad W, El-Manawaty MA, A F Soliman A, Moatasim Y, El Taweel A, Abdelhameed MF, Bekheit MS, Ali MA, Girgis AS. Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties. Bioorg Chem. 2021 12; 117:105466.
-
Burashnikov A, Barajas-Martinez H, Cox R, Demitrack MA, Fossler MJ, Kramer M, Kleiman RB, Kowey P, Antzelevitch C. Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk. Heart Rhythm. 2021 12; 18(12):2177-2186.
-
Wagner A, White AP, Tang MC, Agarwal S, Stueckle TA, Rojanasakul Y, Gupta RK, Dinu CZ. Incineration of Nanoclay Composites Leads to Byproducts with Reduced Cellular Reactivity. Sci Rep. 2018 Jul 16; 8(1):10709.
-
Barbarino M, Cesari D, Intruglio R, Indovina P, Namagerdi A, Bertolino FM, Bottaro M, Rahmani D, Bellan C, Giordano A. Possible repurposing of pyrvinium pamoate for the treatment of mesothelioma: A pre-clinical assessment. J Cell Physiol. 2018 09; 233(9):7391-7401.
-
Gopalakrishnapillai A, Kolb EA, McCahan SM, Barwe SP. Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. Leuk Res. 2017 07; 58:91-97.
-
Gersey ZC, Rodriguez GA, Barbarite E, Sanchez A, Walters WM, Ohaeto KC, Komotar RJ, Graham RM. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer. 2017 02 04; 17(1):99.
-
Desai S, Jamieson FB, Patel SN, Seo CY, Dang V, Fediurek J, Navaranjan D, Deeks SL. The Epidemiology of Invasive Haemophilus influenzae Non-Serotype B Disease in Ontario, Canada from 2004 to 2013. PLoS One. 2015; 10(11):e0142179.
-
Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT. Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers. Chem Biol. 2015 Nov 19; 22(11):1491-1504.
-
Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer. 2016 Feb; 63(2):276-86.
-
Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun; 62(6):1106-9.